Back to search

Switzerland· 66808001

Trelegy Ellipta, Einzeldosiertes Pulver zur Inhalation

A vilanterol, umeclidinium bromid und fluticason furoat product containing fluticasoni furoas, umeclidinium, vilanterolum, registered in Switzerland by GlaxoSmithKline AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC R03AL08

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedTrelegy Ellipta, Einzeldosiertes Pulv…ATCR03AL08REGISTER NO.66808001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Vilanterol, umeclidinium bromid und fluticason furoat is registered in 11 of 19 countries.

Countries holding a registration under ATC R03AL08 (vilanterol, umeclidinium bromid und fluticason furoat), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 7 of them publish a price we can compare per daily dose

Vilanterol, umeclidinium bromid und fluticason furoat · ATC R03AL08

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
fluticasoni furoas, umeclidinium, vilanterolum
Manufacturer
GlaxoSmithKline AG
Country
Switzerland (CH)
ATC code
R03AL08
ATC class
Vilanterol, Umeclidinium bromid und Fluticason furoat
Swissmedic category
B
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680668080014
    30 Dos
    CHF 76.8

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/188ce601-e48c-4134-9f18-74768164b7eb
GET /v1/drugs/188ce601-e48c-4134-9f18-74768164b7eb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "fluticasoni furoas 92 mcg + umeclidinium 55 mcg + vilanterolum 22 mcg",
  "valid_from": "2019-01-01",
  "limitations": "[{\"description\":\"Für Patienten mit moderater COPD nach ≥ 1 Exazerbation trotz einer mindestens 3 Monate dauernder optimierter Therapie unter LABA/LAMA mit Eosinophilenzellzahl im Blut ≥ 100 Zellen/µl, welche nicht ausreichend eingestellt sind<br>\\n<b>oder</b><br>\\nfür Patienten mit moderater bis schwerer COPD nach ≥ 2 moderaten Exazerbationen oder 1 Exazerbation, welche zu einer Hospitalisation geführt hat trotz einer mindestens 3 Monaten dauernden optimierter Therapie unter ICS/LABA oder LABA/LAMA (für LABA/LAMA mit Eosinophilenzellzahl im Blut ≥ 100 Zellen/µl), welche nicht ausreichend eingestellt sind<br>\\n<b>oder</b><br>\\nfür Patienten mit COPD, welche bereits mit einer Kombination von LABA/LAMA und ICS oder ICS/LABA und LAMA mit mehreren Inhalatoren therapiert werden.<br>\\n<br>\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2019-01-01\"}]",
  "galenic_form": "Inh Plv 92/55/22mcg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2019-01-01",
  "self_retention_pct": 10
}

See everything about vilanterol, umeclidinium bromid und fluticason furoat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.